Autopsy report · NCT05049161

A Long-term Extension of Study GNC-401

“Drug product unavailability”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 33 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

GeNeuro Innovation SAS

Sponsor type

Industry

Conditions

Multiple Sclerosis

Interventions

Temelimab 18 mg/kg; Temelimab 36mg/kg; Temelimab 54 mg/kg

Participants

33

Sites

1

Countries

Sweden

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.